Literature DB >> 3131864

Depression of neutrophil function induced by viruses and its role in secondary microbial infections.

J S Abramson1, E L Mills.   

Abstract

A large body of evidence has accumulated indicating that viruses can predispose animal and human hosts to secondary local and systemic bacterial and fungal disease. The mechanism by which viruses cause these superinfections involves both a direct effect of viruses on the tissues at the site of infection and alterations in cells involved in immune surveillance. The effect of viruses on lymphocytes, monocytes, and macrophages has recently been reviewed. A number of viruses have been shown to depress various functions of polymorphonuclear leukocytes, which are critical for controlling bacterial and fungal infections. The alterations in functions of polymorphonuclear leukocytes induced by different viruses include abnormalities of adherence, chemotaxis, phagocytic, oxidative, secretory, and bactericidal activities. The effect of various viruses on neutrophils and the role that virus-induced neutrophil dysfunction has in predisposing the host to secondary infections are reviewed.

Entities:  

Mesh:

Year:  1988        PMID: 3131864     DOI: 10.1093/clinids/10.2.326

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  28 in total

1.  Effect of Friend leukemia virus infection on susceptibility to Candida albicans.

Authors:  M A Moors; S M Jones; K K Klyczek; T J Rogers; H R Buckley; K J Blank
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

Review 2.  Lessons learned and unlearned in periodontal microbiology.

Authors:  Ricardo Teles; Flavia Teles; Jorge Frias-Lopez; Bruce Paster; Anne Haffajee
Journal:  Periodontol 2000       Date:  2013-06       Impact factor: 7.589

3.  A hampered chemoattractant-induced cytoskeletal rearrangement in granulocytes of patients with unexplained severe chronic and relapsing infections of the upper and lower airways. In vitro restoration by G-CSF exposure.

Authors:  P M J Kalkman; W J Fokkens; H J de Wit; J P van de Merwe; H Hooijkaas; J M W van Haarst; H C Hoogsteden; H A Drexhage
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.

Authors:  Michael S Chaussee; Heather R Sandbulte; Margaret J Schuneman; Frank P Depaula; Leslie A Addengast; Evelyn H Schlenker; Victor C Huber
Journal:  Vaccine       Date:  2011-04-08       Impact factor: 3.641

5.  Effects of parainfluenza type 3 virus on guinea pig pulmonary alveolar macrophage functions in vitro.

Authors:  P A Henricks; B Van Esch; F Engels; F P Nijkamp
Journal:  Inflammation       Date:  1993-12       Impact factor: 4.092

6.  Respiratory syncytial virus infection and meningococcal disease.

Authors:  J M Stuart; K Cartwright; N J Andrews
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

7.  Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis.

Authors:  S M Kuhn; J Preiksaitis; G J Tyrrel; T Jadavji; D Church; H D Davies
Journal:  Can J Infect Dis       Date:  2001-01

8.  A case of Aspergillus fumigatus peritonitis complicating liver transplantation.

Authors:  J S Sartin; M P Wilhelm; M R Keating; K Batts; R A Krom
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

9.  Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden.

Authors:  B Lönnqvist; J Palmblad; P Ljungman; G Grimfors; M Järnmark; R Lerner; C Nyström-Rosander; G Oberg
Journal:  Support Care Cancer       Date:  1993-05       Impact factor: 3.603

10.  Lipopolysaccharide restores anti-Candida albicans growth inhibition activity of polymorphonuclear neutrophils from retrovirus-immunosuppressed mice.

Authors:  Y Yamamoto; S Specter; H Friedman
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.